Valneva SE (NASDAQ:VALN – Get Free Report) gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $6.98, but opened at $6.81. Valneva shares last traded at $6.95, with a volume of 12,500 shares trading hands.
The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Valneva in a report on Friday, February 28th.
Institutional Trading of Valneva
A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN lifted its holdings in Valneva SE (NASDAQ:VALN – Free Report) by 14.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 246,766 shares of the company’s stock after acquiring an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned 0.30% of Valneva worth $1,079,000 as of its most recent SEC filing. 11.39% of the stock is currently owned by institutional investors.
Valneva Price Performance
The stock has a market cap of $589.14 million, a price-to-earnings ratio of -55.77 and a beta of 1.93. The stock’s 50 day moving average price is $6.29 and its two-hundred day moving average price is $5.61. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.
About Valneva
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Recommended Stories
- Five stocks we like better than Valneva
- How to Calculate Options Profits
- 4 Undervalued Growth Stocks to Buy and Hold for the Long Term
- Election Stocks: How Elections Affect the Stock Market
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Why Invest in High-Yield Dividend Stocks?
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
